GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (OTCPK:CALA) » Definitions » E10

Calithera Biosciences (Calithera Biosciences) E10 : $-34.79 (As of Dec. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Calithera Biosciences's adjusted earnings per share data for the three months ended in Dec. 2022 was $-1.450. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-34.79 for the trailing ten years ended in Dec. 2022.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-09), Calithera Biosciences's current stock price is $0.02. Calithera Biosciences's E10 for the quarter that ended in Dec. 2022 was $-34.79. Calithera Biosciences's Shiller PE Ratio of today is .


Calithera Biosciences E10 Historical Data

The historical data trend for Calithera Biosciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calithera Biosciences E10 Chart

Calithera Biosciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -34.79

Calithera Biosciences Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -34.79

Competitive Comparison of Calithera Biosciences's E10

For the Biotechnology subindustry, Calithera Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calithera Biosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calithera Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Calithera Biosciences's Shiller PE Ratio falls into.



Calithera Biosciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Calithera Biosciences's adjusted earnings per share data for the three months ended in Dec. 2022 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=-1.45/125.2218*125.2218
=-1.450

Current CPI (Dec. 2022) = 125.2218.

Calithera Biosciences Quarterly Data

per share eps CPI Adj_EPS
201212 0.000 96.871 0.000
201306 0.000 98.518 0.000
201309 -8.407 98.790 -10.656
201312 -10.355 98.326 -13.187
201403 -10.512 99.695 -13.204
201406 -6.915 100.560 -8.611
201409 -6.598 100.428 -8.227
201412 -7.616 99.070 -9.626
201503 -8.800 99.621 -11.061
201506 -8.800 100.684 -10.945
201509 -9.800 100.392 -12.224
201512 -8.800 99.792 -11.042
201603 -10.400 100.470 -12.962
201606 -11.000 101.688 -13.546
201609 -8.800 101.861 -10.818
201612 -9.000 101.863 -11.064
201703 -4.400 102.862 -5.356
201706 -3.000 103.349 -3.635
201709 -3.400 104.136 -4.088
201712 -6.200 104.011 -7.464
201803 -7.400 105.290 -8.801
201806 -1.800 106.317 -2.120
201809 -10.400 106.507 -12.227
201812 -10.200 105.998 -12.050
201903 -12.200 107.251 -14.244
201906 -11.600 108.070 -13.441
201909 -7.600 108.329 -8.785
201912 -7.800 108.420 -9.009
202003 -7.600 108.902 -8.739
202006 -5.800 108.767 -6.677
202009 -6.400 109.815 -7.298
202012 -6.400 109.897 -7.292
202103 -5.600 111.754 -6.275
202106 -3.860 114.631 -4.217
202109 -3.010 115.734 -3.257
202112 -18.400 117.630 -19.588
202203 -3.600 121.301 -3.716
202206 -1.590 125.017 -1.593
202209 -2.010 125.227 -2.010
202212 -1.450 125.222 -1.450

Add all the adjusted EPS together and divide 10 will get our e10.


Calithera Biosciences  (OTCPK:CALA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Calithera Biosciences E10 Related Terms

Thank you for viewing the detailed overview of Calithera Biosciences's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Calithera Biosciences (Calithera Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.
Executives
Deepika Pakianathan director, 10 percent owner 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Takeda Ventures, Inc. 10 percent owner 9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Keith Orford officer: SR. VP, CLINICAL DEVELOPMENT CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Jonathan G Drachman director 21823 30TH DRIVE SE, BOTHELL WA 98021
Susan Molineaux director, officer: PRESIDENT AND CEO C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Christopher Molineaux officer: SR. VP, DEVELOPMENT CALITHERA BIOSCIENCES, 343 OYSTER POINT, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Emil Kuriakose officer: CHIEF MEDICAL OFFICER 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Millennium Pharmaceuticals Inc 10 percent owner 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Stephanie Wong officer: VP, FINANCE 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104